NephroGenex (NRXGQ) Stock Price, News & Analysis

Company Overview

NephroGenex, Inc. was a clinical-stage pharmaceutical company focused on developing therapies for kidney diseases, particularly diabetic nephropathy, a complication of diabetes that can lead to chronic kidney failure.

The company’s principal product candidate was Pyridorin (pyridoxamine dihydrochloride), an orally administered, investigational treatment derived from vitamin B6. NephroGenex studied Pyridorin for its potential to address processes associated with diabetic kidney disease, including oxidative stress and the formation of advanced glycation end products.

NephroGenex conducted clinical development activities in the United States, including mid- and late-stage studies of Pyridorin. Publicly available information indicates that the company later experienced financial difficulties and entered bankruptcy proceedings. Current information about its operations, leadership, commercial activities and geographic presence is limited, and there is no reliable indication that Pyridorin is an approved or commercially available product.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2,000 shs
• Average Volume: 26,223 shs
• Market Capitalization: $36 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NRXGQ
• Previous Symbol: NASDAQ:NRX
• CIK: 1338095
• Web: www.nephrogenex.com
• Phone: +1-609-5538887
• Fax: N/A
• Employees: 1,700
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 12,950,000
• Free Float: N/A
• Market Cap: $36 thousand
• Optionable: Not Optionable
• Beta: N/A